Scaffold Searching of FDA and EMA-Approved Drugs Identifies Lead Candidates for Drug Repurposing in Alzheimer’s Disease
Clinical trials of novel therapeutics for Alzheimer’s Disease (AD) have consumed a significant amount of time and resources with largely negative results. Repurposing drugs already approved by the Food and Drug Administration (FDA), European Medicines Agency (EMA), or Worldwide for another indicatio...
Những tác giả chính: | Sergey Shityakov, Ekaterina V. Skorb, Carola Y. Förster, Thomas Dandekar |
---|---|
Định dạng: | Bài viết |
Ngôn ngữ: | English |
Được phát hành: |
Frontiers Media S.A.
2021-10-01
|
Loạt: | Frontiers in Chemistry |
Những chủ đề: | |
Truy cập trực tuyến: | https://www.frontiersin.org/articles/10.3389/fchem.2021.736509/full |
Những quyển sách tương tự
-
In silico repurposing of FDA-approved drugs as multi-target inhibitors of glioblastoma
Bằng: Ridwan Abiodun Salaam, et al.
Được phát hành: (2025-03-01) -
A Transcriptomics-Based Bioinformatics Approach for Identification and In Vitro Screening of FDA-Approved Drugs for Repurposing against Dengue Virus-2
Bằng: Madhura Punekar, et al.
Được phát hành: (2022-09-01) -
Editorial: Adopting drug repurposing to overcome drug resistance in cancer
Bằng: Eswar Shankar, et al.
Được phát hành: (2023-04-01) -
Network-based drug repurposing for potential stroke therapy
Bằng: Qihui Wu, et al.
Được phát hành: (2023-01-01) -
Approved drugs successfully repurposed against Leishmania based on machine learning predictions
Bằng: Rafeh Oualha, et al.
Được phát hành: (2024-09-01)